Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 18k
22 March 2019
Question for written answer E-001463-19
to the Commission
Rule 130
Ramón Luis Valcárcel Siso (PPE)

 Subject:  A shortage of cancer medicines in Romania
 Answer in writing 

In recent years, Romania has been experiencing a shortage of essential medicines in the fight against cancer, especially in childhood oncology units. This shortage may be due to excessive exports of pharmaceutical products, which translates into a lack of supplies within the country itself. Sometimes this has forced patients to obtain certain medicines by their own means.

The European Parliament warned of this problem in its 2017 resolution on EU options for improving access to medicines and emphasised the importance of the EU developing an information mechanism on the reasons for it. It also called on the Commission to provide a better definition of the concept of shortages and to analyse the causes in detail.

In the light of this:

1. Is the Commission aware of the case of Romania concerning basic oncology drugs?
2. How does the Commission plan to respond to this case, particularly in its role as facilitator for the exchange of resources as conferred on it by the Treaties?
3. In the longer term, how does the Commission intend to make progress on the implementation of the mechanism requested by Parliament, as well as on the creation of strategic plans to combat shortages?

Original language of question: ES 
Last updated: 4 April 2019Legal notice